were deposited in GenBank under accession numbers MF383355 and MF383354, respectively.
Research letters large doses of antibiotics are often necessary with varying degrees of clinical success. There are few data regarding optimal dosing and blood-brain barrier penetration of most agents used for CRE infections. We report a case of post-neurosurgical meningitis due to a carbapenem-resistant Klebsiella pneumoniae, successfully treated with ceftazidime/avibactam in combination with intraventricular gentamicin.
An elderly patient presented with acute-onset headache and loss of consciousness requiring intubation. Imaging revealed diffuse subarachnoid haemorrhage (SAH) and intraventricular haemorrhage with early obstructive hydrocephalus. An external ventricular drain (EVD) was placed at the bedside and cefazolin was prescribed for EVD infection prophylaxis. Therapy was rapidly changed to piperacillin/tazobactam and vancomycin due to suspected aspiration pneumonia after the white blood cell count increased from 10. Persistent fever and leucocytosis were present on day 23 and a bronchial alveolar lavage (BAL) culture grew K. pneumoniae. Piperacillin/tazobactam was changed to 2.5 g of ceftazidime/avibactam intravenously every 8 h and nebulized polymyxin E. On hospital day 26, susceptibility testing established MDR K. pneumoniae and ceftazidime/avibactam was changed to doxycycline. Due to recurrence of fever, EVD cultures were obtained on day 31, revealing MDR K. pneumoniae with susceptibilities matching the BAL isolate (Table 1) . Both isolates were carbapenemase producers determined by CARBA NP (bioMérieux, France) screening per the normal work flow of our microbiology laboratory. Subsequently, ceftazidime/avibactam was restarted, 8 mg of daily intraventricular gentamicin was initiated and the patient underwent an EVD exchange the following day.
All repeat cultures were negative and CSF analyses were trended for the duration of treatment (Table 1 ). Treatment concluded after 21 days of ceftazidime/avibactam and 15 days of intraventricular gentamicin. One day post-completion of ceftazidime/avibactam, the EVD was removed and a ventriculoperitoneal shunt (VPS) was placed. Throughout the hospital stay, the patient remained largely unchanged neurologically. On day 74, the patient was discharged to a long-term care facility, moving spontaneously and responding to voice commands.
The infection rate associated with EVD placement and craniotomy has been reported to be up to 28% and 40%, respectively.
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Common pathogens associated with post-neurosurgical meningitis include staphylococci and Gram-negative bacilli, the latter being increasingly associated with MDR organisms. Antibiotic penetration into the CSF is often poor or unknown, with treatment consisting of systemic and/or intraventricular antibiotics. 1 Mermer et al. described the first documented case of CRE meningitis secondary To our knowledge, there is only one other case report demonstrating the use of ceftazidime/avibactam for the treatment of CRE meningitis. Samuel et al. 4 described the use of 2.5 g of ceftazidime/avibactam intravenously every 6 h as monotherapy for treatment of a KPC-producing K. pneumoniae. Treatment duration was 14 days with resolution of infection. 4 In a rabbit meningitis model, both ceftazidime and avibactam exhibited a 38% mean CSF penetration and the combination decreased CSF bacterial loads by a mean of 5.66 log 10 cfu over 8 h. 5 We describe the third documented CRE meningitis and the second case to be treated with ceftazidime/avibactam. It is not possible to determine the proportion of treatment effect regarding ceftazidime/avibactam versus intraventricular gentamicin. A 10 mg intraventricular dose of gentamicin correlates to peak CSF concentrations of 80 mg/L; however, it is unknown how CSF concentrations compare with serum-based MICs. 6 Numerous reports demonstrate successful outcomes treating Acinetobacter meningitis with intraventricular aminoglycosides, usually in combination with another antibiotic. 7 The optimal treatment duration for MDR meningitis is unclear. IDSA guidelines recommend 10-14 days of treatment for Gramnegative bacilli in shunt infections, but duration may be increased based on clinical response. 8 While 21 days of therapy resulted in successful clearance of infection, it is unknown whether a shorter duration would have resulted in the same outcome for our patient. Table 1 includes a cell index, a tool used to identify and trend ventriculitis in the setting of intraventricular haemorrhage. Increases in the cell index may suggest an infectious process while significant decreases may signify infection clearance. 9 In our patient, the cell index was zero prior to ventriculitis, peaked at 49.2 on treatment day 5 and was once again zero at discontinuation.
CRE are an increasingly prevalent threat in hospitalized patients and become even more difficult to treat in the setting of CNS infection, due to the inadequate and/or unknown CSF penetration of antibiotics. We present the successful use of ceftazidime/avibactam plus intraventricular gentamicin for the treatment of CRE meningitis. Additional clinical and pharmacokinetic studies are needed to investigate the use of ceftazidime/avibactam for this indication.
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